Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers.

Dallinga MG, Yetkin-Arik B, Kayser RP, Vogels IMC, Nowak-Sliwinska P, Griffioen AW, van Noorden CJF, Klaassen I, Schlingemann RO.

Angiogenesis. 2018 Jun 27. doi: 10.1007/s10456-018-9627-4. [Epub ahead of print]

PMID:
29951828
2.

Apoptosis on the move.

Nowak-Sliwinska P, Griffioen AW.

Apoptosis. 2018 Jun;23(5-6):251-254. doi: 10.1007/s10495-018-1462-y. No abstract available.

3.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x. [Epub ahead of print] Review.

4.

An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature.

Huijbers EJM, van Beijnum JR, Lê CT, Langman S, Nowak-Sliwinska P, Mayo KH, Griffioen AW.

Vaccine. 2018 May 17;36(21):3054-3060. doi: 10.1016/j.vaccine.2018.03.064. Epub 2018 Apr 11.

5.

A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.

Wentink MQ, Verheul HMW, Griffioen AW, Schafer KA, McPherson S, Early RJ, van der Vliet HJ, de Gruijl TD.

Vaccine. 2018 Apr 5;36(15):2025-2032. doi: 10.1016/j.vaccine.2018.02.066. Epub 2018 Mar 5.

6.

Different angioregulatory activity of monovalent galectin-9 isoforms.

Aanhane E, Schulkens IA, Heusschen R, Castricum K, Leffler H, Griffioen AW, Thijssen VL.

Angiogenesis. 2018 Aug;21(3):545-555. doi: 10.1007/s10456-018-9607-8. Epub 2018 Mar 2.

PMID:
29500586
7.

Exploration of the platelet proteome in patients with early-stage cancer.

Sabrkhany S, Kuijpers MJE, Knol JC, Olde Damink SWM, Dingemans AC, Verheul HM, Piersma SR, Pham TV, Griffioen AW, Oude Egbrink MGA, Jimenez CR.

J Proteomics. 2018 Apr 15;177:65-74. doi: 10.1016/j.jprot.2018.02.011. Epub 2018 Feb 10.

8.

Apoptosis turns 21.

Griffioen AW, Nowak-Sliwinska P.

Apoptosis. 2017 Dec;22(12):1485-1486. doi: 10.1007/s10495-017-1430-y. No abstract available.

PMID:
29134495
9.

A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7).

van Beijnum JR, Nowak-Sliwinska P, van Berkel M, Wong TJ, Griffioen AW.

Angiogenesis. 2017 Nov;20(4):641-654. doi: 10.1007/s10456-017-9576-3. Epub 2017 Sep 26.

10.

Erratum to: miRNAs: micro-managers of anticancer combination therapies.

van Beijnum JR, Giovannetti E, Poel D, Nowak-Sliwinska P, Griffioen AW.

Angiogenesis. 2017 Nov;20(4):673. doi: 10.1007/s10456-017-9564-7. No abstract available.

11.

A combination of platelet features allows detection of early-stage cancer.

Sabrkhany S, Kuijpers MJE, van Kuijk SMJ, Sanders L, Pineda S, Olde Damink SWM, Dingemans AC, Griffioen AW, Oude Egbrink MGA.

Eur J Cancer. 2017 Jul;80:5-13. doi: 10.1016/j.ejca.2017.04.010. Epub 2017 May 17.

PMID:
28527393
12.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306.

13.

miRNAs: micro-managers of anticancer combination therapies.

van Beijnum JR, Giovannetti E, Poel D, Nowak-Sliwinska P, Griffioen AW.

Angiogenesis. 2017 May;20(2):269-285. doi: 10.1007/s10456-017-9545-x. Epub 2017 May 4. Review. Erratum in: Angiogenesis. 2017 Jul 19;:.

14.

Reply to Marchiò et al.: Antitumor immune regulation by angiostatic therapy.

Wentink MQ, Huijbers EJM, Timmerman P, Griffioen AW.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3166-E3167. doi: 10.1073/pnas.1703074114. Epub 2017 Apr 11. No abstract available.

15.

Angiogenesis inhibitors in combinatorial approaches.

Nowak-Sliwinska P, Griffioen AW.

Angiogenesis. 2017 May;20(2):183-184. doi: 10.1007/s10456-017-9544-y. Epub 2017 Apr 5. No abstract available.

PMID:
28382510
16.

Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.

Berndsen RH, Abdul UK, Weiss A, Zoetemelk M, Te Winkel MT, Dyson PJ, Griffioen AW, Nowak-Sliwinska P.

Angiogenesis. 2017 May;20(2):245-267. doi: 10.1007/s10456-017-9551-z. Epub 2017 Apr 4. Review.

PMID:
28378227
17.

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Ramjiawan RR, Griffioen AW, Duda DG.

Angiogenesis. 2017 May;20(2):185-204. doi: 10.1007/s10456-017-9552-y. Epub 2017 Mar 30. Review.

18.

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.

Rovithi M, Avan A, Funel N, Leon LG, Gomez VE, Wurdinger T, Griffioen AW, Verheul HM, Giovannetti E.

Sci Rep. 2017 Mar 17;7:44686. doi: 10.1038/srep44686.

19.

Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.

Berndsen RH, Weiss A, Abdul UK, Wong TJ, Meraldi P, Griffioen AW, Dyson PJ, Nowak-Sliwinska P.

Sci Rep. 2017 Feb 22;7:43005. doi: 10.1038/srep43005.

20.

The revival of cancer vaccines - The eminent need to activate humoral immunity.

Huijbers EJM, Griffioen AW.

Hum Vaccin Immunother. 2017 May 4;13(5):1112-1114. doi: 10.1080/21645515.2016.1276140. Epub 2017 Jan 24.

21.

Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis.

Maracle CX, Kucharzewska P, Helder B, van der Horst C, Correa de Sampaio P, Noort AR, van Zoest K, Griffioen AW, Olsson H, Tas SW.

Rheumatology (Oxford). 2017 Feb;56(2):294-302. doi: 10.1093/rheumatology/kew393. Epub 2016 Nov 17.

PMID:
27864565
22.

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12532-12537. Epub 2016 Oct 17.

23.

Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.

Kleibeuker EA, Fokas E, Allen PD, Kersemans V, Griffioen AW, Beech J, Im JH, Smart SC, Castricum KC, van den Berg J, Schulkens IA, Hill SA, Harris AL, Slotman BJ, Verheul HM, Muschel RJ, Thijssen VL.

Oncotarget. 2016 Nov 22;7(47):76613-76627. doi: 10.18632/oncotarget.12814.

24.

Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link.

van Beijnum JR, Pieters W, Nowak-Sliwinska P, Griffioen AW.

Biol Rev Camb Philos Soc. 2017 Aug;92(3):1755-1768. doi: 10.1111/brv.12306. Epub 2016 Oct 24. Review.

PMID:
27779364
25.

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth.

Rovithi M, de Haas RR, Honeywell RJ, Poel D, Peters GJ, Griffioen AW, Verheul HM.

J Exp Clin Cancer Res. 2016 Sep 7;35(1):138. doi: 10.1186/s13046-016-0411-2.

26.

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM.

Br J Cancer. 2016 Oct 11;115(8):940-948. doi: 10.1038/bjc.2016.275. Epub 2016 Aug 30.

27.

Sunitinib uptake inhibits platelet function in cancer patients.

Sabrkhany S, Griffioen AW, Pineda S, Sanders L, Mattheij N, van Geffen JP, Aarts MJ, Heemskerk JW, Oude Egbrink MG, Kuijpers MJ.

Eur J Cancer. 2016 Oct;66:47-54. doi: 10.1016/j.ejca.2016.07.016. Epub 2016 Aug 12.

PMID:
27525572
28.

Role of the tumor stroma in resistance to anti-angiogenic therapy.

Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW.

Drug Resist Updat. 2016 Mar;25:26-37. doi: 10.1016/j.drup.2016.02.002. Epub 2016 Feb 24. Review.

PMID:
27155374
29.

A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies.

van Beijnum JR, Thijssen VL, Läppchen T, Wong TJ, Verel I, Engbersen M, Schulkens IA, Rossin R, Grüll H, Griffioen AW, Nowak-Sliwinska P.

Int J Cancer. 2016 Aug 15;139(4):824-35. doi: 10.1002/ijc.30131. Epub 2016 May 5.

30.

A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.

Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P.

J Thorac Oncol. 2016 May;11(5):758-68. doi: 10.1016/j.jtho.2016.01.014. Epub 2016 Feb 2.

31.

Optimization of drug combinations using Feedback System Control.

Nowak-Sliwinska P, Weiss A, Ding X, Dyson PJ, van den Bergh H, Griffioen AW, Ho CM.

Nat Protoc. 2016 Feb;11(2):302-15. doi: 10.1038/nprot.2016.017. Epub 2016 Jan 14.

32.

Platelets: an unexploited data source in biomarker research.

Sabrkhany S, Kuijpers MJ, Verheul HM, Griffioen AW, oude Egbrink MG.

Lancet Haematol. 2015 Dec;2(12):e512-3. doi: 10.1016/S2352-3026(15)00225-2. Epub 2015 Dec 3. No abstract available.

PMID:
26686404
33.

Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis.

Van Mourik TR, Läppchen T, Rossin R, Van Beijnum JR, Macdonald JR, Mayo KH, Griffioen AW, Nicolay K, Grüll H.

Anticancer Res. 2015 Nov;35(11):5945-54.

PMID:
26504018
34.

A streamlined search technology for identification of synergistic drug combinations.

Weiss A, Berndsen RH, Ding X, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P.

Sci Rep. 2015 Sep 29;5:14508. doi: 10.1038/srep14508.

35.

Anticancer Organometallic Osmium(II)-p-cymene Complexes.

Păunescu E, Nowak-Sliwinska P, Clavel CM, Scopelliti R, Griffioen AW, Dyson PJ.

ChemMedChem. 2015 Sep;10(9):1539-47. doi: 10.1002/cmdc.201500221. Epub 2015 Jul 14.

PMID:
26190176
36.

CD44 enhances tumor aggressiveness by promoting tumor cell plasticity.

Paulis YW, Huijbers EJ, van der Schaft DW, Soetekouw PM, Pauwels P, Tjan-Heijnen VC, Griffioen AW.

Oncotarget. 2015 Aug 14;6(23):19634-46.

37.

Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains.

Nowak-Sliwinska P, Clavel CM, Păunescu E, te Winkel MT, Griffioen AW, Dyson PJ.

Mol Pharm. 2015 Aug 3;12(8):3089-96. doi: 10.1021/acs.molpharmaceut.5b00417. Epub 2015 Jul 21.

PMID:
26158308
38.

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E.

Cancer Immunol Res. 2015 Sep;3(9):1017-29. doi: 10.1158/2326-6066.CIR-14-0244. Epub 2015 May 26.

39.

Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Bajou K, Herkenne S, Thijssen VL, D'Amico S, Nguyen NQ, Bouché A, Tabruyn S, Srahna M, Carabin JY, Nivelles O, Paques C, Cornelissen I, Lion M, Noel A, Gils A, Vinckier S, Declerck PJ, Griffioen AW, Dewerchin M, Martial JA, Carmeliet P, Struman I.

Nat Med. 2015 May;21(5):537. doi: 10.1038/nm0515-537a. No abstract available.

PMID:
25951534
40.

In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia.

Clavel CM, Nowak-Sliwinska P, Păunescu E, Griffioen AW, Dyson PJ.

Chem Sci. 2015 May 1;6(5):2795-2801. doi: 10.1039/c5sc00613a. Epub 2015 Mar 17.

41.

Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer.

Punt S, Houwing-Duistermaat JJ, Schulkens IA, Thijssen VL, Osse EM, de Kroon CD, Griffioen AW, Fleuren GJ, Gorter A, Jordanova ES.

Mol Cancer. 2015 Mar 31;14:71. doi: 10.1186/s12943-015-0350-0.

42.

A common sugar-nucleotide-mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6F-GalNAc (Ac3).

van Wijk XM, Lawrence R, Thijssen VL, van den Broek SA, Troost R, van Scherpenzeel M, Naidu N, Oosterhof A, Griffioen AW, Lefeber DJ, van Delft FL, van Kuppevelt TH.

FASEB J. 2015 Jul;29(7):2993-3002. doi: 10.1096/fj.14-264226. Epub 2015 Apr 13.

43.

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.

Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL.

Cancer Med. 2015 Jul;4(7):1003-15. doi: 10.1002/cam4.441. Epub 2015 Mar 31.

44.

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P.

Angiogenesis. 2015 Jul;18(3):233-44. doi: 10.1007/s10456-015-9462-9. Epub 2015 Apr 1.

45.

Galectin expression in cancer diagnosis and prognosis: A systematic review.

Thijssen VL, Heusschen R, Caers J, Griffioen AW.

Biochim Biophys Acta. 2015 Apr;1855(2):235-47. doi: 10.1016/j.bbcan.2015.03.003. Epub 2015 Mar 25. Review.

PMID:
25819524
46.

Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.

Păunescu E, Clavel CM, Nowak-Sliwinska P, Griffioen AW, Dyson PJ.

ACS Med Chem Lett. 2015 Jan 30;6(3):313-7. doi: 10.1021/ml500496u. eCollection 2015 Mar 12.

47.

Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes.

Clavel CM, Păunescu E, Nowak-Sliwinska P, Griffioen AW, Scopelliti R, Dyson PJ.

J Med Chem. 2015 Apr 23;58(8):3356-65. doi: 10.1021/jm501655t. Epub 2015 Apr 7.

PMID:
25812075
48.

The great escape; the hallmarks of resistance to antiangiogenic therapy.

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW.

Pharmacol Rev. 2015;67(2):441-61. doi: 10.1124/pr.114.010215. Review.

49.

Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.

Weiss A, Bonvin D, Berndsen RH, Scherrer E, Wong TJ, Dyson PJ, Griffioen AW, Nowak-Sliwinska P.

Sci Rep. 2015 Mar 11;5:8990. doi: 10.1038/srep08990.

50.

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.

Nowak-Sliwinska P, Weiss A, van Beijnum JR, Wong TJ, Kilarski WW, Szewczyk G, Verheul HM, Sarna T, van den Bergh H, Griffioen AW.

Cell Death Dis. 2015 Feb 12;6:e1641. doi: 10.1038/cddis.2015.4.

Supplemental Content

Loading ...
Support Center